Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Cipher Banking On Absorica, Literally

By Jason Napodano, CFA

This morning, Cipher Pharmaceuticals (DND.TO) (CPHMF.PK) posted an updated investor presentation on its website. It shows that business is chugging along nicely at Cipher. Back in May 2013, we announced that we were raising our earnings forecasts for the company, yet again, after a solid first quarter 2013 report. In the first quarter 2013, Cipher delivered $3.3 million in revenues and $1.5 million in net income (+6 cents per share). Revenues increased by 82% over the first quarter 2012. It was the fifth quarter in a row of greater than 80% year-over-year revenue growth and the fifth quarter in a row of positive earnings per share.

The new investor presentation highlights many of the impressive business...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details